an intraindividual comparative multiple-dose study ( 6 days ) was carried out under controlled conditions on 10 healthy volunteers in order to establish the bioavailability of bendroflumethiazide ( bft ; 3-benzyl-6-trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzoth iad iazine-1 , 1-oxide ) , the sum of the fluorogenic metabolites of spironolactone ( 3- [ 3-oxo-7-alpha-acetylthio-17 beta-hydroxy-4-androstene-17-alpha-yl ] -propionic acid-gamma-lactone ) and canrenone , the main spironolactone metabolite from a fixed combination of bft with spironolactone vs. the commercial preparations of the single drugs .
C0022947
lactone
C0037982
spironolactone